vidarabine phosphate has been researched along with Breast Neoplasms in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (80.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Biagiotti, S; De Marco, C; Dominici, S; Magnani, M; Orlotti, N; Pierigè, F; Rossi, L; Serafini, S; Zaffaroni, N | 1 |
Bodey, GP; Kavanagh, JJ; Krakoff, IH | 1 |
Carpenter, JT; Raney, M; Vogel, CL; Wang, G | 1 |
Ahmed, T; Arlin, Z; Arnold, P; Ashikari, R; Mittelman, A; Savona, S | 1 |
Clark, GM; Diehl, V; Lathan, B; von Hoff, DD | 1 |
1 trial(s) available for vidarabine phosphate and Breast Neoplasms
Article | Year |
---|---|
Phase II evaluation of fludarabine in patients with metastatic breast cancer: a Southeastern Cancer Study Group trial.
Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Middle Aged; Neoplasm Metastasis; Vidarabine Phosphate | 1986 |
4 other study(ies) available for vidarabine phosphate and Breast Neoplasms
Article | Year |
---|---|
Cytotoxic activity of 2-Fluoro-ara-AMP and 2-Fluoro-ara-AMP-loaded erythrocytes against human breast carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arabinonucleotides; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cytotoxins; DNA, Neoplasm; Drug Delivery Systems; Drug Evaluation, Preclinical; Erythrocytes; Female; Flow Cytometry; Humans; Time Factors; Vidarabine Phosphate | 2010 |
Phase I study of fludarabine (2-fluoro-ara-AMP).
Topics: Adult; Aged; Agranulocytosis; Antimetabolites, Antineoplastic; Arabinonucleotides; Breast Neoplasms; Choriocarcinoma; Drug Evaluation; Female; Humans; Middle Aged; Pregnancy; Rhabdomyosarcoma; Sarcoma, Ewing; Thrombocytopenia; Uterine Cervical Neoplasms; Uterine Neoplasms; Vidarabine Phosphate | 1985 |
Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleotides; Breast Neoplasms; Drug Evaluation; Female; Humans; Middle Aged; Vidarabine Phosphate | 1988 |
Cytotoxic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5-monophosphate (fludarabine, NSC 312887) in a human tumor cloning system.
Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Breast Neoplasms; Cell Survival; Dose-Response Relationship, Drug; Female; Humans; Lymphoma, Non-Hodgkin; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vidarabine Phosphate | 1988 |